Our Companies

Filter

Recent Offerings Click each tile for more information

*The firm acted as placement agent in each of these transactions. This list includes all deals from 2020 forward and is presented in alphabetical order. US$ Amounts raised includes Ceros, Selected Dealers, and Company introduced investors. The inclusion of a deal on this list does not imply performance success or guarantee future results. Past offerings are not indicative of future investment opportunities or outcomes. Transactions listed here do not constitute an offer to buy or sell securities.
*Private placements are available only to accredited investors as defined under SEC Regulation D and may involve significant risks, including illiquidity and loss of principal.

Our Story

We raise capital for disruptive healthcare companies.

Chris Dewey and Mark Goldwasser worked together to set up Robotic Ventures in 2000- 2001. Two of the material investments were iRobot and Z-KAT Inc. iRobot had an initial public offering in 2005. While involved with Z-KAT, Chris Dewey recruited Maurice Ferre. Together they built MAKO SURGICAL which went public in February 2008 and was then sold to STRYKER for $1.65 billion in 2014. Chris personally has invested alongside Maurice Ferre, Fred Moll, and David Matlin. This led to the formation of DGB (Chris Dewey, Mark Goldwasser, and Dave Brown) who, in 2019, purchased Ceros Financial Services. In 2022, Roger Monteforte joined Ceros as a Partner and Vice-Chairman and the Forte Capital Group became a division and launched Innovation X Advisors, LLC, an RIA that advises the privately held Innovation X Funds.

* Early stage investing in these types of companies can carry significant risk of total loss of principal, and not all investments made by these investors historically have been successful. Past performance is not indicative of future results.
img

Letter from CEO

Mark Goldwasser, Chief Executive Officer

I am proud to say that 2024 was another landmark year for Ceros Financial Services and its affiliates with combined record revenue of over $100 million and assets under management and administration exceeding $8 billion. The Ceros Group has become a formidable full-service wealth management boutique consisting of Advisors Preferred, At-Cap, Innovation X Advisors LLC, and Ceros Capital Markets. Ceros delivers a robust platform of services designed to meet the demands of today’s advisor.

Our team has made it possible to offer a broad array of services and products for RIA’s, retail, and institutional customers. This vision that DGB (Chris Dewey, Mark Goldwasser, and Dave Brown) had in 2019 when we purchased Ceros remains in place and has been surpassed in many areas, including the existing RIA business that Catherine Ayers-Rigsby and the Ceros team had originally built.

In 2022, Roger Monteforte joined Ceros as a Partner and Vice-Chairman, and the Forte Capital Group became a division, launching Innovation X Advisors, LLC, an RIA that advises the privately held Innovation X Funds. Innovation X Advisors, through the private funds, currently hold $2B of AUM and has raised over $900M for companies such as Stripe, SpaceX, and OpenAI.

Advisors Preferred, LLC provides advisory services to our Open-End Mutual Funds, and At-Cap Partners serves as an advisor to our retail advisory clients.

Corporate RIA’s can streamline operations, compliance functions, and cost. Mutual Funds can use Advisors Preferred to promote their brand, execute strategy, and realize success in the mutual fund marketplace. We can act as an advisor to the funds as well as providing a Shared Trust. Ceros provides distribution services for the Advisors Preferred funds. This offering is backed by a distinguished ownership and management group and a boutique feel, yet a high level of service.

Ceros Capital Markets specializes in fundraising (primarily Series A-D) for MedTech companies that are developing disruptive technologies, particularly for diagnostic and non-invasive procedures in the medical device, robotic, biotech, and digital health sectors. Our unique portfolio of companies features ventures identified in their early stages by some of the most experienced MedTech entrepreneurs who understand the synergies between innovation and healthcare. The common mission is often to reduce overall costs to the industry, increase doctor and nurse efficiency, while improving patient care. Ceros’ clients have the opportunity to invest in companies that are pushing the boundaries of technology, disrupting the medical industry, and fueling innovation to help change lives.

In addition to adding investment opportunities for our existing advisors as well as attracting new advisors seeking comprehensive solutions for their discerning clients, we will focus on expanding the company’s core business of mutual funds, RIA, and wealth management.

Israeli companies have always been part of our core focus, and we plan on growing our current industry playbook to include other technologies that we believe will provide significant opportunities for Ceros and our clients in the venture capital markets.

The Ceros office footprint now encompasses most of the US East Coast (New York, Connecticut, Maryland, and South Florida), and our client base is in all 50 States. I would like to thank all our clients and colleagues for contributing to a successful 2024 and look forward to a successful 2025 and the continued growth of our firm as we build on our achievements.

img

Mark Goldwasser

Leading Innovation
in Key Sectors

Medical Devices

Innovative solutions for
life-saving procedures

Surgical Robotics

Advancing surgical precision
with minimally invasive robotics.

Digital Health

Improving patient care through
smart digital solutions.

In the news

profile
Mark Goldwasser at IATI Mini Mixiii Miami 2025: Investing in Disruptive, AI, Robotics & MedTech

Mark Goldwasser, CEO of Ceros Financial Services, discusses raising $300M+ for disruptive, noninvasive, robotic, and AI-driven companies at IATI Mini Mixiii Miami 2025.Read More

profile
DERMASENSOR
Simplifying Skin Cancer Detection

(TIME) DermaSensor’s titular device is the first of its kind cleared by the FDA for use by non-specialist physicians. It uses optical spectroscopy—the deployment of light to analyze tissues—to promptly detect likely cancerous skin lesions at a rate similar to that of in-person dermatologists.

Read More

profile
DERMASENSOR
US FDA clears DermaSensor's AI-powered skin cancer detecting device

(Reuters) Privately-held device maker DermaSensor said on Wednesday that the U.S. Food and Drug Administration had cleared its hand-held device that uses artificial intelligence to detect skin cancer.

Read More

profile
DERMASENSOR
FDA Clears AI-Powered Handheld Device That Can Detect Skin Cancer

(Forbes) The FDA has cleared DermaSensor’s first-of-its-kind handheld device that uses artificial intelligence to non-invasively detect skin cancer, the Miami-based device maker announced Wednesday.

Read More

Contact Us

Thank you for your interest in Ceros Capital Markets. We look forward to speaking with you shortly.

Speak with Ceros Reprensentative

Learn more about our opportunities. We do not share data.

If you’re a client and need assistance, please contact us directly at (866) 842-3356.